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Reactions of gold(III) dichloride complexes (containing ancillary cyclo-aurated aryl-
amine or -pyridine ligands) with various catechols and excess trimethylamine base 
gives a series of gold(III) catecholate compexes; related complexes containing 
dioxolene ligands were prepared from the ,-diketone 
SCH(CO2Et)C(O)C(O)CH(CO2Et). Several complexes show high activity against 
P388 leukaemia cells.      
           
 
Abstract 
The reactions of the cyclometallated gold(III) complexes [LAuCl2] [L = 
(dimethylaminomethyl)phenyl, 2-benzylpyridyl or 2-anilinopyridyl] with catechol, 
tetrachlorocatechol, or the cyclic ,-diketone SCH(CO2Et)C(O)C(O)CH(CO2Et) 
gives stable complexes containing five-membered Au-O-C-C-O rings.  These 
represent the first examples of well-characterised gold(III) catecholate complexes.  
Similarly, reactions with 2-acetamidophenol [HOC6H4NHC(O)CH3] gives 
complexes with the related Au-N-C-C-O ring. The complexes were characterised by 
NMR spectroscopy, electrospray ionisation mass spectrometry, elemental 
microanalysis, and in the case of the complex [(2-
benzylpyridyl)Au{OC6H4NC(O)CH3}] by an X-ray crystal structure determination.  
Several complexes show high activity towards P388 murine leukemia cells. 
 




1.  Introduction 
 
 Since the serendipitous discovery that the simple platinum(II) coordination 
complex cisplatin, cis-[PtCl2(NH3)2] showed potent antitumour activity, a very wide 
range of platinum(II) complexes have been screened.  Today, a range of platinum(II) 
[and platinum(IV)] complexes are available in the clinic for cancer 
chemotherapy.[1,2] The similarity between platinum(II) and the isoelectronic (d
8
) 
gold(III) suggests that certain complexes of the latter metal centre might also have 
promising cytotoxicity,[3] though the cytotoxicity of gold(III) complexes has been 
less studied than gold(I) thus far.[4] Although many simple gold(III) complexes such 
as [AuCl4]
-
 are too strongly oxidising to show useful antitumour properties,[1,5,6] 
derivatives containing cyclo-aurated aryl-amine or aryl-pyridine ligands show much 
greater stability, and are not reduced by sulfur-based ligands such as thiols and 
related ligands.[7-9] This is significant since sulfur-based reductants occur widely in 
the cysteinyl and methionine residues in biological materials. Initial studies in this 
area showed that the gold(III) complexes 1 show good antitumour activity, and both 
the chemistry and biological activity have been evaluated quite extensively.[9-11]   
 We have found that the thiosalicylate analogue 2 also shows good activity 
against P388 leukaemia cells,[7] though other derivatives containing alternative 
cyclo-aurated ligands did not show such good activity.[12] As part of the 
continuation of our studies in this area, in this paper we report the synthesis and 
evaluation of complexes containing bidentate, oxygen-donor catecholate ligands.  
While oxygen donor ligands are widely used in platinum anticancer agents (e.g. 
cyclobutane-1,1-dicarboxylate in carboplatin), the increased lability of the gold(III) 
centre compared to platinum(II) [5,13] suggests that the use of less labile ligands 
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might be required to maintain activity in the gold system.  It was reasoned that the 
use of catecholate ligands might achieve this aim. 
 Little appears to have been previously reported on alkoxo complexes of 
gold(III) in general [14], or specifically in the area of catecholate complexes. A 
combination of catechol and aniline has been reported to extract gold(III) from HCl 
solution by formation of a gold(III) catecholate complex [15] but no gold(III) 
catecholate complexes have yet been characterised. 
 
2.  Results and discussion 
 
2.1 Synthesis of gold(III) catecholate complexes 
 
 Reactions of the readily prepared cyclo-aurated gold(III) dichloride 
complexes 3a and 3b with an excess of catechol (1,2-dihydroxybenzene, 
pyrocatechol) or tetrachlorocatechol, together with an excess of trimethylamine base 
in hot methanol gave the catecholate complexes 4a - 4d which were isolated in an 
analytically pure state. In the same manner, complex 5 was prepared from 1a and 
catechol.  The preferred reaction method involves addition of the base to a 
suspension of the appropriate catechol and gold(III) complex in hot methanol, 
whereupon the gold(III) complex rapidly reacts and dissolves, followed by rapid 
precipitation of the product in most cases. The tetrachlorocatecholate derivatives 4c 
and 4d, and compounds containing the 2-anilinopyridyl ligand (viz. 4a), have 
relatively poor solubility in alcohols and chlorinated solvents, and were isolated by 
direct filtration from the reaction mixture.  However the benzylpyridyl catecholate 
complex 4b was more soluble, and was precipitated from the reaction solution with 
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water. Complex 5 did not immediately precipitate from the reaction solution upon 
addition of water, but red-brown microcrystals were deposited on slow evaporation 
of the solution at room temperature over several days. The compounds were isolated 
as orange to brown solids, which are moisture-stable, and appear to be reasonably 
light-stable.  Satisfactory elemental microanaytical data were obtained for all 
complexes.  The tetrachlorocatecholate complexes 4c and 4d were too insoluble in 
all common deuterated solvents for NMR spectroscopic characterisation to be 
carried out. Complexes 4a and 4b gave [M + X]
+
 and [2M + X]
+
 (X = H, Na) ions in 
their positive ion electrospray (ES) mass spectra. 
 In order to prepare derivatives with improved solubility characteristics, to 
facilitate both characterisation and biological testing, we turned our attention to 
complexes of commercially available 3,5-di-tert-butylcatechol.  The reaction of 3a 
with an excess of this catechol in the presence of excess trimethylamine gave a 
brown microcrystalline solid which gave excellent microanalytical data for the 
desired product. The positive-ion ES mass spectrum of the product yielded the 
expected [M + H]
+
, [M + Na]
+
 and [2M + Na]
+
 ions.  However, the 
1
H NMR 
spectrum of the crude product indicated that two isomers were produced (in an 
approximate ratio 3:2), which presumably have the 3-tert-butyl substituent syn or 
anti to the pyridine nitrogen, viz structures 6a and 6b.  However, assignment of 
resonances to individual isomers was not made. 
 The ligand 2-acetamidophenol is an analogue of a catechol, except that one 
OH group is replaced by an NHC(O)CH3 group, which can act as a nitrogen donor 
ligand upon deprotonation.  Using the same methodology as above, reaction of 3a 
and 3b with 2-acetamidophenol and excess trimethylamine gave the derivatives 7a 
and 7b respectively. These complexes were isolated as air- and light-stable yellow 
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solids in moderate yields, which give satisfactory microanalytical data and the 
expected ions in the positive ion ES mass spectra. 
1
H NMR spectra indicate that a 
single product is formed in each case. On the basis of a single crystal X-ray 
diffraction study (described in section 2.2), coupled with NMR spectroscopic 
characterisation on 7b, the complexes are assigned the geometry which places the 
two lowest trans-influence donor ligand groups, namely the phenolate oxygen and 
the pyridine nitrogen, mutually cis. Other gold(III) complexes containing mixed 
donor ligand sets are well-known to show such antisymbiosis.[7, 16]  The phenolate 
oxygen is assigned a lower trans influence than the NC(O)CH3 group on the basis of 
1
J(PtP) coupling constants in related platinum(II)-phosphine complexes of 
catecholate [17] and amidate [18] ligands. 




C NMR assignments of 7b was 
derived from detailed analyses of one and two-dimensional NMR data, including 
DEPT135, COSY, TOCSY, SELTOCSY, NOEDIFF, NOESY, SELNOESY, 
gHSQC and HMBC spectral data.  The atom numbering scheme is given in Figure 1, 
with protons bearing the same number to the carbon to which they are attached.  The 
full NMR assignment is given in Table 1. COSY, TOCSY and 1D-SELTOCSY data 
traced out three independent proton spin systems attributable to H-2, H-3, H-4 and 
H-5 ( 7.59, 7.08, 7.16 and 7.18 respectively), H-9, H-10, H-11 and H-12 ( 7.71, 
8.02, 7.56 and 9.27 respectively) and H-14, H-15, H-16 and H-17 ( 6.83, 6.94, 6.63 
and 7.64 respectively).   The marked downfield shift experienced by H-12 ( 9.27) 
can be attributed to the proximity of this proton to the N1 atom.   
The H-7 methylene protons ( 4.29) exhibited NOESY and 1D-SELNOESY 
correlations strong to the H-5 ( 7.18) and H-9 ( 7.71) and a weak correlation to the 
protons of H-20 methyl group ( 2.02).  The methyl group protons exhibited 
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NOEDIFF, NOESY and 1D-SELNOESY correlations to H-2 ( 7.59) and H-17 ( 
7.64).  The foregoing considerations lead to a unique assignment of the 6 doublet-
like and 6 triplet-like 
3
J coupled aryl proton signals (J = 5.9 to 8.0 Hz), each of 
which also exhibited a resolvable 
4
J coupling (J = 1.2 to 2.5 Hz).  Thereafter 
consideration of correlations observed in the gHSQC spectrum for protonated 
carbons, and in the gHMBC spectrum for protonated and quaternary carbons lead to 
an unequivocal assignment of the 
13
C NMR resonances of  7b. The resonances of the 
C-8 ( 156.1), C-13 ( 160.6) and C-18 ( 143.1) atoms were consistent with the 
location of these atoms adjacent to the N1, O1 and N2 atoms respectively. 
 Complexes 8a and 8b derived from the ,-diketone 
SCH(CO2Et)C(O)C(O)CH(CO2Et) ligand were also synthesised using the same 
methodology, and were fully characterised.  This diketone has been found to 
coordinate to both platinum(II) [17] and rhodium(III) [19] as a dioxolene dianion, 
giving a five-membered M-O-C-C-O ring system related to the catecholate ligand.  
An attractive feature of this type of complex is the potential to vary the solubility 
characteristics by simple variation of the ester substituent, however, in this study, 
only the ethyl ester derivative was used. The symmetrical nature of the ligand is also 
attractive in preventing the formation of mixtures of isomers. 
 The aliphatic region in the 
1
H NMR spectrum of complex 8b showed two 
distinct multiplets at  4.3 and 1.3.  The former consists of two quartets (due to the 
inequivalent ethyl ester CH2 groups) and one overlapping singlet due to the CH2 
group of the benzylpyridyl ligand.  Likewise, the multiplet at  1.3 consists of two 
overlapping triplets, due to the inequivalent ethyl CH3 groups. Two CH2 ( 60.1 and 







NMR spectrum of 8b. The slight inequivalence of these ethyl groups occurs due to 
the asymmetric nitrogen-carbon coordination at the gold centre. 
  
2.2  X-ray structure of complex [(2-benzylpyridyl)Au{N(COCH3)C6H4O}] 7b 
 
 An X-ray crystal structure determination was carried out on this complex, in 
order to confirm the mode of binding of the N,O donor to the gold(III) centre. 
Suitable crystals (orange plates) were obtained by diffusion of diethyl ether into a 
dichloromethane solution of the complex.  The complex crystallises with two 
independent molecules in the unit cell. The structure determination confirms the 
formulation of the complex as a gold(III) complex of the doubly deprotonated 
CH3CONHC6H4OH ligand. Figure 1 shows the atom labelling scheme for molecule 
1, and selected bond lengths and angles for both molecules are given in Table 2. The 
two molecules are fairly similar, the main difference being the conformation of the 
six-membered ring involving the gold and the benzylpyridyl ligand.  In molecule 1 
(illustrated) the CH2 group is pointing down, but in molecule 2 (in the same 
orientation) it is pointing up.  This puckered ring system is typical for the 
benzylpyridyl ligand, as observed previously in the dichloride 3b.[20] 
 The gold centres have a slightly distorted square-planar geometry, as 
expected, with the sum of bond angles around the gold atoms in molecules 1 and 2 
being 361.6 and 360.5° respectively.  In both molecules, the two longest Au-X 
bonds are to the pyridine nitrogen [Au(1)-N(1) 2.053(6) Å] and the phenolate 
oxygen [Au(1)-O(1) 2.055(5) Å].  These are respectively trans to higher trans 
influence amidate and aryl ligands.  The Au-NC(O)CH3 bond distances [Au(1)-N(2) 
2.008(6) Å and Au(2)-N(4) 2.014(7) Å] are very comparable with the Au-
 
9 
NC(O)CH3 bond distance trans to the NMe2 group in the gold(III) ureylene 
derivative 9 [2.014(5) Å].[21] 
 
2.3  Biological activity of gold(III) catecholate and related complexes 
 
 Antituour activity against murine P388 leukemia cells, together with 
antibacterial activity against three selected bacteria (Eschericia coli, Bacillus subtilis 
and Pseudomonas aeruginosa) and three fungi (Candida albicans, Trichophyton 
mentagrophytes and Cladosprium resinae) was determined for the benzylpyridyl 
complexes 4b, 7b and 8b (which had greatest solubility) together with the di-tert-
butyl catecholate derivative 6, and the benzylamine catecholate derivative 5. Data 
are summarised in Table 3. 
 High antitumour activity was shown by the catecholate complexes 4b and 5, 
and the di-tert-butylcatecholate mixture 6. The other derivatives tested, with 
acetamidophenolate and dioxolene ligands, showed only moderate activity.  In the 
antimicrobial assays, both the catecholate 4b and acetamidophenolate 7b complexes 
showed high activity against a number of organisms, but there appeared to be some 
selectivity, with both compounds showing highest activity against Bacillus subtilis 
and Pseudomonas aeruginosa, and much lower activity against Trichophyton 
mentagrophytes and Cladosporium resinae. Complex 5 also showed considerable 
activity against Trichophyton mentagrophytes, Bacillus subtilis and Candida 
albicans. The mixture 6a/6b showed little antimicrobial activity. Overall, these 
results are highly promising and suggest that a more detailed study of the biological 
activity of this general class of complex could identify complexes with improved 
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biological activities. A study of related metallacyclic derivatives of gold(III) could 
also prove fruitful. 
 
3.  Experimental 
 




H NMR spectra were recorded at 300.13 MHz on a Bruker AC300 
spectrometer in CDCl3 unless otherwise stated, with the exception of 7b and 8b. 
One- and two-dimensional NMR spectra for 7b and 8b were determined at 27
o
C 
using a Bruker DRX400 spectrometer fitted with Z-axis pulse field gradient 
hardware and an inverse 5 mm probehead.  Bruker supplied pulse programs were 




C, DEPT135, COSY, TOCSY, SELTOCSY, NOEDIFF, 
NOESY, SELNOESY, gHSQC and gHMBC spectral data.  Chemical shifts are 
reported relative to TMS where  CHCl3 = 7.26 ppm (
1




Electrospray mass spectra were recorded on a VG Platform II instrument in 
positive-ion mode, using methanol as the mobile phase. A cone voltage of 50 V was 
found to give optimal spectral intensity and clarity.  Infrared spectra were recorded 
as KBr disks on a BioRad FTS40  spectrometer.  Melting points were determined on 
a Reichert-Jung hotstage apparatus and are uncorrected. Elemental analyses were 
obtained by the University of Otago Campbell Microanalytical Laboratory. 
 All reactions were carried out in laboratory reagent grade methanol without 
further purification. Dichloromethane and diethyl ether were purified by distillation 
from calcium hydride and sodium-benzophenone ketyl respectively.  Complex 1a 
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was prepared by the literature procedure [22]. Complexes 3a and 3b were prepared 
by minor modifications of the literature procedures [23, 24] excepting that longer 
reaction times were employed (24 and 16 h respectively). The cyclic diketone 
SCH(CO2Et)C(O)C(O)CH(CO2Et) was prepared by the literature procedure.[17] 
Catechol (BDH), tetrachlorocatechol monohydrate (Aldrich), 3,5-di-tert-
butylcatechol (Aldrich), 2-acetamidophenol (Aldrich) and aqueous trimethylamine 
(BDH, 25-30% w/v) were used as supplied. 
 
3.2  Synthesis of complex 4a 
 
 Aqueous trimethylamine (2 mL, excess) was added to a mixture of 3a (200 
mg, 0.458 mmol) and catechol (100 mg, 0.909 mmol) in hot methanol (30 mL), and 
the mixture was refluxed for 20 min. giving an orange solution which deposited 
orange-brown microcrystals.  After cooling to room temperature, the product was 
filtered off, washed with cold methanol (15 mL) and dried under vacuum for 2 h to 
give 187 mg (86%) of 4a.  M.p. > 230 ˚C (decomp.). Found: C, 42.7; H, 3.6; N, 5.8. 
C17H13N2AuO2 requires C, 43.1; H, 2.8; N, 5.9%. ESMS: (Cone voltage = 50 V) m/z 
475 (30%, [M + H]
+
), 497 (100%, [M + Na]
+
), 949 (10%, [2M + H]
+





H NMR:  9.1 (1H, d, 3J = 6.54 Hz), 8.0 (1H, d, 3J = 8.1 Hz), 7.9 (1H, 
d, 
3
J = 7.8 Hz), 7.3 (1H, d, 
3
J = 8.6 Hz), 7.3 (1H, t, 
3
J = 7.4 Hz), 7.1 (1H, d, 
3
J = 7.9 
Hz), 7.0 (2H, overlapping t + t), 6.5 (1H, d, 
3
J = 7.5 Hz), 6.5 (1H, d, 
3
J = 7.6 Hz), 
6.4 (1H, t, 
3
J = 7.4 Hz), 6.3 (1H, t, 
3







3.3  Synthesis of complex 4b 
 
 Aqueous trimethylamine (2 mL, excess) was added to a hot mixture of 3b 
(200 mg, 0.149 mmol) and catechol (100 mg, 0.909 mmol) in hot methanol (30 mL), 
and the mixture was refluxed for 20 min. giving a brown solution.  Water (40 mL) 
was added and after cooling to room temperature the resulting orange-brown 
microcrystals were filtered off, washed with water (5 mL) and diethyl ether (10 mL) 
and dried under vacuum for 2 h to give 147 mg (68%) of 4b. The product was 
recrystallised by vapour diffusion of diethyl ether into a dichloromethane solution of 
the complex. M.p. 158 - 160 ˚C. Found: C, 45.6; H, 2.8; N, 2.9. C18H14NAuO2 
requires C, 45.6; H, 3.0; N, 3.0%. ESMS: (Cone voltage = 50 V) m/z 474 (55%, [M 
+ H]
+
), 496 (25%, [M + Na]
+
), 947 (30%, [2M + H]
+





NMR:  9.3 (1H, d, 3J = 5.2 Hz), 8.1 (1H, t, 3J = 7.7 Hz), 7.8 (1H, d, 3J = 6.4 Hz),  
7.7 (1H, d, 
3
J = 7.6 Hz), 7.5 (1H, t, 
3
J = 6.7 Hz), 7.2 (3H, m, overlapping d + t + t), 
6.8 (1H, d, 
3
J = 7.6 Hz), 6.7 (1H, d, 
3
J = 7.7 Hz), 6.6 (1H, t, 
3
J = 7.4 Hz), 6.5 (1H, t, 
3
J = 7.4 Hz). 
 
3.4  Synthesis of complex 4c 
 
 Following the method for 4a, an orange-brown powder (259 mg, 91%) was 
obtained starting from 3a (200 mg, 0.458 mmol), tetrachlorocatechol monohydrate 
(200 mg, 0.752 mmol) and aqueous trimethylamine (2 mL, excess). M.p. > 230 ˚C 
(decomp.). Found: C, 33.4; H, 1.9; N, 4.5. C17H13N2AuCl4O2 requires C, 33.1; H, 




3.5  Synthesis of complex 4d 
 
 Following the method for 4a, a brown powder (215 mg, 76%) was obtained 
starting from 3b (200 mg, 0.459 mmol), tetrachlorocatechol monohydrate (200 mg, 
0.752 mmol) and aqueous trimethylamine (2 mL, excess). M.p. > 230 ˚C (decomp.). 
Found: C, 34.2; H, 1.5; N, 2.3. C18H14NAuCl4O2 requires C, 35.2; H, 2.3; N, 2.3%. 
 
3.6  Synthesis of complex 5 
 
 A suspension of 1a (200 mg, 0.498 mmol) with catechol (200 mg, 1.82 
mmol) in methanol (30 mL) with trimethylamine (2 mL) was refluxed for 20 min. 
giving a dark orange-brown solution. Water (50 mL) was added, and the solution 
cooled and allowed to slowly evaporate at room temperature.  After several days, 
dark red-brown microcrystals had formed, which were filtered off, washed with 
water, and dried under vacuum. Yield 60 mg (27%). M.p. 126 - 128 °C. Found: C, 
40.4; H, 3.9; N, 2.9. C15H16NAuO2 requires C, 41.0; H, 3.7; N, 3.2%. ESMS: (Cone 
voltage = 50 V) m/z 440 (100%, [M + H]
+
), 879 (20%, [2M + H]
+





H NMR:  7.61-6.52 (m, Ph), 4.28 (s, 2H, CH2), 3.36 (s, 6H, CH3). 
 
3.7  Synthesis of complex 6a/6b 
 
 Following the method for 4a, brown microcrystals (234 mg, 87%) were 
obtained starting from 3a (200 mg, 0.458 mmol), 3,5-di-tert-butylcatechol (150 mg, 
0.676 mmol) and aqueous trimethylamine (2 mL, excess). The product was 
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recrystallised by vapour diffusion of diethyl ether into a dichloromethane solution of 
the complex. M.p. 159 - 160 ˚C. Found: C, 51.3; H, 4.7; N, 4.8. C25H29N2AuO2 
requires C, 51.2; H, 5.0; N, 4.8%. ESMS: (Cone voltage = 50 V) m/z 586 (45%, [M 
+ H]
+
), 609 (100%, [M + Na]
+
), 1173 (10%, [2M + H]
+




3.8  Synthesis of complex 7a 
 
 Following the method for 4a, yellow microcrystals (192 mg, 81%) were 
obtained starting from 3a (200 mg, 0.458 mmol), 2-acetamidophenol (100 mg, 0.662 
mmol) and aqueous trimethylamine (2 mL, excess). M.p. > 230 ˚C (decomp.). 
Found: C, 44.1; H, 3.0; N, 8.1. C19H16N3AuO2 requires C, 44.3; H, 3.1; N, 8.2%.  
ESMS: (Cone voltage = 50 V) m/z 516 (55%, [M + H]
+
), 538 (100%, [M + Na]
+
), 




3.9  Synthesis of complex 7b 
 
 A mixture of 3b (200 mg, 0.149 mmol), 2-acetamidophenol (100 mg, 0.662 
mmol) and aqueous trimethylamine (2 mL, excess) in methanol (30 mL) was 
refluxed for 20 min. giving a brown solution. Water (40 mL) was added and the 
orange solution left to crystallise for 2 days. The resulting yellow microcrystals were 
filtered, washed with water (15 mL) and dried under vacuum for 2 h to give 199 mg 
(84%) of 7b.  The product was recrystallised by vapour diffusion of diethyl ether 
into a dichloromethane solution of the complex.  M.p. 159 - 162 ˚C.  Found: C, 46.7; 
H, 3.1; N, 5.3. C20H17N2AuO2 requires C, 46.7; H, 3.3; N, 5.5%.  ESMS: (Cone 
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voltage = 50 V) m/z 515 (65%, [M + H]
+
), 537 (100%, [M + Na]
+
), 1029 (20%, [2M 
+ H]
+




3.10  Synthesis of complex 8a 
 
 Following the method for 4a, an orange-brown powder (229 mg, 80%) was 
obtained starting from 3a (200 mg, 0.458 mmol), SCH(CO2Et)C(O)C(O)CH(CO2Et) 
(120 mg, 0.465 mmol) and aqueous trimethylamine (2 mL, excess). M.p. > 230 ˚C 
(decomp.). Found: C, 40.5; H, 2.9; N, 4.4. C21H19N2AuO6S requires C, 40.4; H, 3.1; 
N, 4.5%. IR: (CO region) 1658 cm-1 (vs). 
 
3.11  Synthesis of complex 8b 
 
 Following the method for 4a, a yellow-brown powder (232 mg, 81%) was 
obtained starting from 3b (200 mg, 0.459 mmol), SCH(CO2Et)C(O)C(O)CH(CO2Et) 
(120 mg, 0.465 mmol) and aqueous trimethylamine (2 mL, excess). M.p. 172 - 174 
˚C. Found: C, 41.5; H, 3.0; N, 2.1. C22H20NAuO6S requires C, 42.4; H, 3.2; N, 
2.3%. IR: (CO region) 1680 cm-1 (vs). ESMS: (Cone voltage = 50 V) m/z 624 
(10%, [M + H]
+
), 646 (100%, [M + Na]
+




H NMR:  9.2 
(d, 
3
J = 5.8 Hz), 8.1 (t, 
3
J = 7.7 Hz), 7.8 (d, 
3
J = 7.3 Hz), 7.7 (d, 
3
J = 7.4 Hz), 7.6 (t, 
3
J = 6.4 Hz), 7.2 (t, 
3
J = 7.0 Hz), 7.1 (m, overlapping t + t), 4.3 (CH2, q, 
3
J = 7.1 
Hz), 4.3 (CH2, m, overlapping q + s), 1.4 (CH3, t, 
3










3.12  X-ray structure determination on complex 7b 
 
 Crystals were obtained by vapour diffusion of diethyl ether into a 
dichloromethane solution of the complex at room temperature. 
 Unit cell parameters and intensity data were collected using a Siemens 
SMART CCD diffractometer, using standard collection procedures, with 
monochromatic Mo-K X-rays (0.71073 Å). Corrections for absorption and other 
effects were carried out with SADABS.[25] All other calculations used the 
SHELX97 programs.[26]  The structure was solved by direct methods, and 
developed with refinement based on F
2
. The complex crystallises with two 
independent molecules in the unit cell.  Selected bond lengths and angles are given 
in Table 1.  Crystal, data collection and refinement details for the structure 
determination are given in Table 4. 
 The similarity in the scattering factors of nitrogen and carbon potentially 
hampers discrimination between the elements in the C(1) and N(1) positions 
[likewise for C(31) and N(3)] and analysis of bond parameters in the structure 
provided no clear distinction of the two elements. The assignment provided is based 
on analysis of the Uiso values of the atoms, 0.023, 0.024, 0.026 and 0.023 for N(1), 
C(1), N(3), and C(31) respectively.  The alternative arrangement in which the N(1) 
and C(1) atoms are interchanged provides Uiso values of 0.014, 0.033, 0.017 and 







3.13  Biological assays 
 
Assays were carried out by the commercial service offered by the Marine 
Chemistry Group, Department of Chemistry, Canterbury University, New Zealand.  
Samples were dissolved in 3:1 methanol-dichloromethane prior to testing.  
Antitumour assays were carried out by determining, by means of a two-fold dilution 
series, the concentration of sample in ng mL
-1
 required to reduce the cell growth of 
the P388 leukemia cell line (ATCC CCL 46) by 50%. The sample of interest was 
incubated for 72 h with the P388 Murine Leukemia cells. IC50 values were 
determined by measurement of the absorbance values when the yellow dye MTT 
tetrazolium is reduced by healthy cells to the purple dye MTT formazan.  Mitomycin 
C was included in the assays as a positive control. 
 The antimicrobial assays were carried out by measuring the inhibition zone 
as an excess radius (mm) from a 6 mm diameter filter paper disk containing 2 
micrograms of sample, which was placed on a seeded agar plate containing the 
organism tested. 
 
4.  Supplementary material 
  
 Crystallographic data (excluding structure factors) for the structure described 
in this paper have been deposited with the Cambridge Crystallographic Data Centre, 
CCDC number ######. Copies of the data can be obtained free of charge on 
application to The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: 
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C NMR assignments ( ppm in CDCl3) 







1 C 135.9   
2 CH 133.6 7.59 br d, J = 7.7 Hz 
3 CH 127.6 7.08 ddd, J =7.7, 6.5, 2.5 Hz 
4 CH 127.9 7.16 ~td, J = 7.4, 1.2 Hz 
5 CH 127.6 7.18 m (overlapped by H-4) 
6 C 131.0   
7 CH2 47.4 4.29 s (2H) 
8 C 156.2   
9 CH 126.1 7.71 br d, J = 7.7 Hz 
10 CH 141.9 8.02 ~td J = 7.7, 1.5 Hz 
11 CH 124.3 7.56 ddd, J = 5.9, 7.4, 1.5 Hz 
12 CH 149.5 9.27 dd, J = 5.9, 1.5 Hz 
13 C 160.6   
14 CH 116.1 6.83 ddd, J = 8.0, 1.4 Hz 
15 CH 125.3 6.94 ddd, J = 8.0, 7.2, 1.5 Hz 
16 CH 116.1 6.63 ddd, J = 7.9, 7.2, 1.4 Hz 
17 CH 124.1 7.64 dd, J = 7.9, 1.5 Hz 
18 C 143.1   
19 C=O 173.8   
20 CH3 27.6 2.02 s (3H) 
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Table 2.  Selected bond lengths (Å) and bond angles (°) for [(2-
benzylpyridyl)Au{N(COCH3)C6H4O}] 7b;  data for both independent molecules 
are listed for comparison. 
 
Molecule 1     Molecule 2 
 
Au(1)-C(1)  2.005(7)  Au(2)-C(31)  2.018(7) 
Au(1)-N(1)  2.053(6)  Au(2)-N(3)  2.042(6) 
Au(1)-O(1)  2.055(5)  Au(2)-O(3)  2.053(5) 
Au(1)-N(2)  2.008(6)  Au(2)-N(4)  2.014(7) 
O(1)-C(13)  1.352(9)  O(3)-C(43)  1.363(10) 
N(2)-C(18)  1.447(9)  N(4)-C(48)  1.439(10) 
 
N(1)-Au(1)-O(1)  90.8(2)  N(3)-Au(2)-O(3)  89.9(2) 
O(1)-Au(1)-N(2)  83.3(2)  O(3)-Au(2)-N(4)  83.4(3) 
N(2)-Au(1)-C(1)  97.8(3)  N(4)-Au(2)-C(31)  99.5(3) 
C(1)-Au(1)-N(1)  89.7(3)  C(31)-Au(2)-N(3)  87.7(3) 
Au(1)-O(1)-C(13)  109.0(4) Au(2)-O(3)-C(43)  108.4(4) 
Au(1)-N(2)-C(18)  109.3(5) Au(2)-N(4)-C(48)  108.3(5) 
N(2)-C(18)-C(13)  115.0(6) N(4)-C(48)-C(43)  116.1(7) 
O(1)-C(13)-C(18)  119.5(6) O(3)-C(43)-C(48)  118.9(7) 




Table 4.  Crystal, collection and refinement data for the structure determination of 
[(2-benzylpyridyl)Au{N(COCH3)C6H4O}] 7b 
 
Crystal data  
Empirical formula   C20H17AuN2O2 
Formula weight   514.32 
Crystal system    Monoclinic 
Space group    P21/c 
Unit cell dimensions    
a (Å)     18.546(5) 
b (Å)     10.159(3) 
c (Å)     17.768(4)     
b (°)     96.151(3)      
V (Å
3
)     3328.4(14) 
Z     8 
Dc (g cm
-3
)    2.053 
 
Data collection 
Diffractometer   Siemens SMART CCD 
Radiation, wavelength (Å)  Mo-K,  = 0.71073 
Temperature (K)   203(2)  
 range for data collection (°)  2.21 to 26.46 
Reflections collected   42095 






F(000)     1968 
 
Structure analysis and refinement 
Solution by    Direct methods 
Refinement method   Full-matrix least-squares on F
2
 
Data / restraints / parameters  6802 / 0 / 453 
Goodness-of-fit on F2  1.111 
Final R indices [I > 2(I)]  R1 = 0.0479, wR2 = 0.1301 
R indices (all data)   R1 = 0.0514, wR2 = 0.1344   
Largest difference peak (e Å
-3
) 3.137 
Largest difference hole (e Å
-3
) -4.869 
Programs used    SHELXS 97 and SHELXL 97 [26] 
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Caption for Figure 
 
Fig. 1. Molecular structure of molecule 1 of [(2-
benzylpyridyl)Au{N(COCH3)C6H4O}] 7b showing the atom numbering scheme. 
Thermal displacement ellipsoids are depicted at the 50% probability level. 
 
